This segment focuses on the development, manufacturing, and commercialization of rapid, point-of-care molecular diagnostic tests for infectious diseases. Lucira Health's core technology platform enables highly accurate and convenient at-home testing. Research and development efforts are directed towards expanding the test menu to include other prevalent respiratory and sexually transmitted infections. The company leverages reverse transcription loop-mediated isothermal amplification (RT-LAMP) technology for rapid nucleic acid detection. The primary focus is on providing accessible and reliable diagnostic solutions that empower individuals to proactively manage their health and reduce the spread of infectious diseases. Future opportunities include expanding into international markets and developing multiplex assays for simultaneous detection of multiple pathogens.